ANGLE's Parsortix System Demonstrates Broader Ability to Capture Circulating Tumor Cells Versus Other Separation Technologies
April 18 2016 - 7:00AM
Business Wire
Research published online in the
International Journal of Cancer, shows the ParsortixTM
System efficiently captures and harvests intact, viable
circulating tumour cells (CTCs), including EpCAM-negative CTCs, to
allow for broader downstream CTC analysis
A rigorous evaluation by researchers at University Medical
Centre Hamburg-Eppendorf (UKE) of ANGLE’s ParsortixTM cell
separation system has demonstrated significant advantages of its
size and deformability based enrichment technology, versus
marker-based systems. The research was published online on March 26
in the International Journal of Cancer in advance of its print
publication later this year.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160418005217/en/
ANGLE Parsortix cell separation system
(Photo: Business Wire)
The report, A Novel Microfluidic Platform for Size and
Deformability Based Separation and the Subsequent Molecular
Characterization of Viable Circulating Tumor Cells, determined that
the Parsortix System enables isolation of viable CTCs at very high
purity and that are ready for a broad range of molecular and
functional analyses. “The system’s ability to provide numeration
and molecular characterization of EpCAM-negative CTCs will help to
broaden research into the mechanisms of cancer as well as
facilitating the use of CTCs in ‘liquid biopsies,’” the report
stated.
According to co-author Prof. Klaus Pantel, Chairman, Department
of Tumour Biology at UKE’s Centre of Experimental Medicine, systems
that can comprehensively capture not only epithelial CTCs but also
mesenchymal CTCs will play an important role in cancer diagnoses
and subsequent treatment.
“Our findings emphasize the importance of developing new
label-free assays that allow the molecular characterization of CTCs
for therapeutic targets and resistance mechanisms at the DNA, RNA
and protein level,” Pantel said. “This information is vital as
liquid biopsies will help clinicians to adapt therapies to the
individual needs of cancer patients.”
To put Parsortix through its paces, a team of ANGLE researchers
in conjunction with Prof. Pantel, working in Philadelphia, Hamburg
and Dusseldorf analyzed the performance of the epitope-independent
system in capture of tumor cells from blood samples spiked with
five different cancer cell lines, and from multiple patient samples
including metastatic breast, non-metastatic colon, metastatic
colon, metastatic lung, and non-metastatic lung cancer. Using the
system, UKE researchers showed average tumor cell capture ranged
from 42 per cent to 70 per cent with subsequent harvest of the
cells ranging between 54 per cent and 69 per cent of the cells
captured. One of the novel and powerful capabilities that
distinguishes the Parsortix system is that it enables harvest of
captured tumor cells for subsequent further analyses.
Significantly, 99 per cent of the harvested CTCs from both spiked
and patient samples were viable after processing and still
functional for downstream molecular analysis as demonstrated by
mRNA characterization and array based comparative genomic
hybridization.
“The epitope independent Parsortix system enables the isolation
of viable CTCs at a very high purity. Using our system, viable
tumour cells are easily accessible and ready for molecular and
functional analysis,” said Dr George Hvichia, the inventor of the
Parsortix technology and CSO, ANGLE plc. “The system’s ability for
enumeration and molecular characterization of EpCAM-negative CTCs
will help to broaden research into the mechanisms of cancer as well
as facilitating the use of CTCs as liquid biopsies.”
A growing body of evidence has shown that cancer cells in the
process of, or that have completed EMT, have increased invasion
capabilities, which leads to the loss of an epithelial cell
adhesion molecule (EpCAM). Currently, CTC isolation is still mainly
dependent on expression of EpCAM on the surface of cancer cells of
epithelial origin. New research, however, indicates that EMT plays
a significant role in metastasis, and certain EMT cancer cells lose
EpCAM expression. Isolation by techniques that are independent of
marker expression, such as Parsortix, enables capture of those EMT
CTCs, providing a more precise and comprehensive path to diagnosis
and treatment of metastatic cancer.
The results obtained by the collaborating team confirms the
system’s ability to effectively harvest CTCs not only with
epithelial characteristics, but also those in the process of, or
that have completed, epithelial-to-mesenchymal transition (EMT)
across a broad range of cancer types.
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the ParsortixTM system, a cell separation technology that enables a
simple blood test to harvest targeted cells, such as circulating
tumor cells (CTCs) for molecular profiling and analysis.
ParsortixTM can help deliver targeted cancer diagnostics designed
to inform personalized treatment of cancer. It is also designed to
be compatible with existing major medtech analytical platforms and
enable companion diagnostics for major pharma in helping to
identify patients that will benefit from a particular drug and then
monitoring the drug’s effectiveness. ANGLE has established formal
collaborations with world-class cancer centers and is working with
these cancer centers to demonstrate key applications for its
ParsortixTM non-invasive cancer diagnostic system as a liquid
biopsy. In addition to cancer cells, the ParsortixTM technology has
the potential for deployment for other clinically significant cell
types in the future.
ANGLE’s Parsortix system is available for research use worldwide
and is CE-IVDD Marked for indicated clinical use in Europe.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and in the United
States on the OTC-QX market under the ticker symbol ANPCY.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160418005217/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice
PresidentorMedia:Brandwidth Solutions LLCChris Anderson,
207-232-7007canderson@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024